family with sequence similarity 204 member D, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM204DP profile across patient tissues and cancer cell-line models. FAM204DP expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FAM204DP is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, FAM204DP RNA expression shows 6,657 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, and STAD as cancer lineages where FAM204DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM204DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM204DP survival associations across molecular data types. FAM204DP RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM204DP RNA expression–survival associations across cancer types. High FAM204DP expression shows unfavorable associations in CESC, MESO, BLCA, ACC and KICH, but favorable associations in HNSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FAM204DP RNA expression.
This table summarizes FAM204DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM204DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM204DP shows lower tumor expression in STAD. The STAD box plot shows higher FAM204DP RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p = .045).
This table shows molecular features associated with FAM204DP in patient tissues and cancer cell lines. In patient samples, FAM204DP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
